Cargando…

Extended-release oral capsule of carbidopa–levodopa in Parkinson disease

Motor fluctuations complicate the treatment of patients with Parkinson’s disease receiving levodopa. Extended-release carbidopa–levodopa has a pharmacokinetic profile that provides a more continuous levodopa serum concentration. Patients taking this formulation can expect longer duration of action a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Margolesky, Jason, Singer, Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784558/ https://www.ncbi.nlm.nih.gov/pubmed/29399046 http://dx.doi.org/10.1177/1756285617737728

Ejemplares similares

Population Pharmacodynamics of IPX066: An Oral Extended-Release Capsule Formulation of Carbidopa–Levodopa, and Immediate-Release Carbidopa–Levodopa in Patients With Advanced Parkinson’s Disease
por: Mao, Zhongping, et al.
Publicado: (2013)

Comparison of the pharmacokinetics of an oral extended‐release capsule formulation of carbidopa‐levodopa (IPX066) with immediate‐release carbidopa‐levodopa (Sinemet(®)), sustained‐release carbidopa‐levodopa (Sinemet(®) CR), and carbidopa‐levodopa‐entacapone (Stalevo(®))
por: Hsu, Ann, et al.
Publicado: (2015)

Pharmacokinetics of Rytary(®), An Extended-Release Capsule Formulation of Carbidopa–Levodopa
por: Mittur, Aravind, et al.
Publicado: (2017)

Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules
por: Modi, Nishit B., et al.
Publicado: (2019)

Dose‐Response Analysis of the Effect of Carbidopa‐Levodopa Extended‐Release Capsules (IPX066) in Levodopa‐Naive Patients With Parkinson Disease
por: Mao, Zhongping Lily, et al.
Publicado: (2016)

Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease
por: Hauser, Robert A, et al.
Publicado: (2018)

Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy
por: Espay, Alberto J., et al.
Publicado: (2017)

Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome Dyskinesia
por: Hauser, Robert A., et al.
Publicado: (2020)

Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease
por: Sharma, Vibhash D, et al.
Publicado: (2018)

Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation
por: LeWitt, Peter, et al.
Publicado: (2023)

Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa
por: Othman, Ahmed A., et al.
Publicado: (2017)

Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson’s Disease Patients
por: Müller, Thomas, et al.
Publicado: (2022)

Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary(®)): Results of a Nationwide Dose Conversion Survey
por: Hauser, Robert A., et al.
Publicado: (2021)

Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson’s disease
por: Poulopoulos, Markos, et al.
Publicado: (2010)

Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy
por: Loens, Sebastian, et al.
Publicado: (2017)

Implementing Levodopa‐Carbidopa Intestinal Gel for Parkinson Disease: Insights from US Practitioners
por: Burack, Michelle, et al.
Publicado: (2018)

Improvement of Primary Writing Tremor in Parkinson’s Disease with Carbidopa/Levodopa
por: Battista, James P., et al.
Publicado: (2015)

Von Economo’s disease and postencephalitic parkinsonism responsive to carbidopa and levodopa
por: Bigman, Daniel Y, et al.
Publicado: (2018)

Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson’s Disease: Clinical Trial Post Hoc Analyses
por: Pahwa, Rajesh, et al.
Publicado: (2022)

Levodopa/carbidopa and entacapone in the treatment of Parkinson’s disease: efficacy, safety and patient preference
por: Müller, Thomas
Publicado: (2009)

Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety
por: Othman, Ahmed A., et al.
Publicado: (2015)

Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets
por: Othman, Ahmed A, et al.
Publicado: (2014)

Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson's Disease with Motor Fluctuations
por: Morgan, John C., et al.
Publicado: (2018)

Levodopa–carbidopa intrajejunal infusion in Parkinson’s disease: untangling the role of age
por: Morgante, Francesca, et al.
Publicado: (2020)

L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson's Disease: A Randomised Study
por: Stocchi, Fabrizio, et al.
Publicado: (2015)

Intrajejunal vs oral levodopa-carbidopa therapy in Parkinson disease: A retrospective cohort study
por: Popa, Luminita C., et al.
Publicado: (2020)

Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson’s disease
por: Valldeoriola, Francesc, et al.
Publicado: (2021)

The Advantages of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson’s Disease: A Systematic Review
por: Zhang, Xing-Ru, et al.
Publicado: (2020)

Levodopa-Carbidopa Intestinal Gel may improve treatment-resistant freezing of gait in Parkinson’s disease
por: Shackleford, Melanie R., et al.
Publicado: (2022)

Problems related to levodopa‐carbidopa intestinal gel treatment in advanced Parkinson's disease
por: Udd, Marianne, et al.
Publicado: (2017)

Effect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients
por: Antonini, Angelo, et al.
Publicado: (2016)

Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson’s disease patients
por: Senek, Marina, et al.
Publicado: (2018)

Eruptive melanocytic nevi in a patient with Parkinson disease treated by carbidopa-levodopa
por: Haraszti, Samantha, et al.
Publicado: (2018)

Therapeutic Effect of Levodopa/Carbidopa/Entacapone on Sleep Disturbance in Patients with Parkinson’s Disease
por: Park, Kye Won, et al.
Publicado: (2020)

Multicenter study of levodopa carbidopa intestinal gel in Parkinson’s disease: the Turkish experience
por: GÜLTEKİN, Murat, et al.
Publicado: (2020)

Polyneuropathy monitoring in Parkinson's disease patients treated with levodopa/carbidopa intestinal gel
por: Pauls, K. Amande M., et al.
Publicado: (2021)

Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review
por: Tsunemi, Taiji, et al.
Publicado: (2021)

Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
por: Brooks, David J
Publicado: (2008)

Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off
por: Kuoppamäki, Mikko, et al.
Publicado: (2015)

Levodopa/carbidopa: Hallucinations: case report
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8v74mkjo265iaa0bkjesd2193r